Work

Roluperidone monotherapy, a treatment for negative symptoms in schizophrenia

Year: 2025

Type: article

Abstract: Roluperidone is a drug in development targeting primary negative symptoms in schizophrenia, which binds sigma-2, 5-HT2A, and alpha1a receptors. Roluperidone administered as monotherapy to patients suffering from mild to moderate negative symptoms and withdrawal from antipsychotic drugs, improved negative symptoms in 2 clinical trials. The patients who were symptomatically stable for 3 or 6 months before antipsychotic drug withdrawal showed a very low rate of psychotic symptoms worsening over 6 or 9-month trial duration. Focus: Treatment of primary negative symptoms in a subgroup of patients suffering from schizophrenia.

Source: The International Journal of Neuropsychopharmacology

DOI: 10.1093/ijnp/pyaf032

Authors: Michael Davidson, Nadine Noel, Florent Schmitt, Remy Luthringer

Institutions: University of Nicosia, Minerva Neurosciences (United States)

Language: English

Topic: Schizophrenia research and treatment

Subfield: Psychiatry and Mental health

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,693